N. Ghilezan

693 total citations
26 papers, 535 citations indexed

About

N. Ghilezan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, N. Ghilezan has authored 26 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in N. Ghilezan's work include Cancer Treatment and Pharmacology (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Colorectal Cancer Treatments and Studies (6 papers). N. Ghilezan is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Colorectal Cancer Treatments and Studies (6 papers). N. Ghilezan collaborates with scholars based in Romania, Austria and Hungary. N. Ghilezan's co-authors include Tudor–Eliade Ciuleanu, Valentina Tzekova, Mislav Grgić, Christoph Zielinski, Christoph Wiltschke, Thomas Brodowicz, Victoria Soldatenkova, Mária Wagnerová, M. Wenczl and Ernst Ulsperger and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

N. Ghilezan

22 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Ghilezan Romania 8 368 317 103 98 76 26 535
I. Garassino Italy 13 271 0.7× 342 1.1× 40 0.4× 106 1.1× 51 0.7× 28 547
François Casteillo France 11 204 0.6× 197 0.6× 55 0.5× 71 0.7× 32 0.4× 30 366
Erika Tóth Hungary 12 211 0.6× 106 0.3× 65 0.6× 94 1.0× 33 0.4× 65 456
Mathieu Minsat France 12 142 0.4× 148 0.5× 156 1.5× 196 2.0× 35 0.5× 31 454
Kristie J. Paris United States 12 137 0.4× 188 0.6× 71 0.7× 275 2.8× 92 1.2× 28 470
Benedetta Agresti Italy 12 137 0.4× 166 0.5× 185 1.8× 130 1.3× 41 0.5× 36 467
J Skołyszewski Poland 12 154 0.4× 172 0.5× 51 0.5× 148 1.5× 126 1.7× 59 433
Hiroyuki Kawakami Japan 11 205 0.6× 179 0.6× 29 0.3× 184 1.9× 35 0.5× 32 441
J. Cheng United States 12 331 0.9× 148 0.5× 58 0.6× 97 1.0× 83 1.1× 27 504
Louis Bazire France 9 123 0.3× 85 0.3× 131 1.3× 92 0.9× 29 0.4× 24 344

Countries citing papers authored by N. Ghilezan

Since Specialization
Citations

This map shows the geographic impact of N. Ghilezan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Ghilezan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Ghilezan more than expected).

Fields of papers citing papers by N. Ghilezan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Ghilezan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Ghilezan. The network helps show where N. Ghilezan may publish in the future.

Co-authorship network of co-authors of N. Ghilezan

This figure shows the co-authorship network connecting the top 25 collaborators of N. Ghilezan. A scholar is included among the top collaborators of N. Ghilezan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Ghilezan. N. Ghilezan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cebotaru, C., et al.. (2012). P1.16 Detection of Circulating Tumor Cells Could Adjust Therapy in Poor Risk Germ Cell Tumors? A Pilot Study. Annals of Oncology. 23. v17–v17. 1 indexed citations
2.
Ciuleanu, Tudor–Eliade, et al.. (2012). First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study.. PubMed. 7(1). 43–6. 1 indexed citations
3.
Ciuleanu, Tudor–Eliade, et al.. (2012). Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study.. PubMed. 9(2). 161–5. 12 indexed citations
4.
Nagy, Viorica, et al.. (2009). Radiotherapy versus Concurrent 5-Day Cisplatin and Radiotherapy in Locally Advanced Cervical Carcinoma. Strahlentherapie und Onkologie. 185(3). 177–183. 25 indexed citations
5.
Kacsó, Gabriel, Zsolt Fekete, S S Popescu, et al.. (2008). Long Term Results of Curative Intent Chemoradiation for Muscle Invading Bladder Cancer. International Journal of Radiation Oncology*Biology*Physics. 72(1). S341–S341. 1 indexed citations
6.
Ciuleanu, E., et al.. (2008). Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.. PubMed. 13(1). 37–42. 26 indexed citations
7.
Nagy, Viorica, et al.. (2008). Quality of life and treatment related toxicity in 335 patients with locally advanced cervical carcinoma treated by two chemoradiation regimens.. PubMed. 12(3). 389–94. 6 indexed citations
8.
Ciuleanu, Tudor–Eliade, et al.. (2007). Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.. PubMed. 12(1). 33–9. 5 indexed citations
9.
Brodowicz, Thomas, Maciej Krzakowski, Matjaž Zwitter, et al.. (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 52(2). 155–163. 256 indexed citations
10.
Plataniotis, George, Anna Kalogera‐Fountzila, N. Ghilezan, et al.. (2004). Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. International Journal of Radiation Oncology*Biology*Physics. 59(4). 1018–1026. 55 indexed citations
11.
12.
13.
14.
Vinholes, J., Fernando Palacios Salas, E. Mickiewicz, et al.. (2001). A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis. European Journal of Cancer. 37. S167–S167. 9 indexed citations
15.
Ioan, A, et al.. (2000). Integration of surgery in the pluridisciplinary approach of non-small cell cancer patients improves the outcome. Lung Cancer. 29(1). 124–124. 2 indexed citations
16.
Ciuleanu, Tudor–Eliade, et al.. (1999). Taxol and cisplatin (TP) versus etoposide cisplatin (EP) in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 35. S251–S252. 1 indexed citations
17.
18.
Ghilezan, N., et al.. (1986). [The paraglottic space, a little known route for spreading in laryngeal cancer].. PubMed. 31(2). 117–22.
19.
Ghilezan, N., et al.. (1982). [Involvement of the central nervous system in malignant lymphoma].. PubMed. 23(4). 375–86. 2 indexed citations
20.
Ghilezan, N., et al.. (1976). Telecobalt Therapy for Malignant Lung Tumours. Acta Radiologica Therapy Physics Biology. 15(5). 394–400.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by I. Garassino Breakdown of academic impact, for papers by François Casteillo Breakdown of academic impact, for papers by Erika Tóth Breakdown of academic impact, for papers by Mathieu Minsat Breakdown of academic impact, for papers by Kristie J. Paris Breakdown of academic impact, for papers by Benedetta Agresti Breakdown of academic impact, for papers by J Skołyszewski Breakdown of academic impact, for papers by Hiroyuki Kawakami Breakdown of academic impact, for papers by J. Cheng Breakdown of academic impact, for papers by Louis Bazire
Rankless by CCL
2026